The Food and Drug Administration advisory panel unanimously voted Friday afternoon to recommend the Johnson & Johnson’s COVID-19 vaccine for an emergency use authorization. For eight hours, the group of independent experts had reviewed the safety and efficacy of the vaccine. READ: FDA finds Johnson & Johnson vaccine effectively prevents COVIDWhile the Johnson & Johnson vaccine is less effective than Pfizer and Moderna’s vaccines, the experts noted that no one who received the Johnson & Johnson vaccine was hospitalized or died from coronavirus. READ: Here’s what makes J&J vaccine different than the othersAdStudies in children are planned with the older group of children expected to begin receiving the vaccine as soon as early March. There are also additional studies planned in immunocompromised people.